NCT04773522: Phase 1 - JNJ-64407564 in Japanese Participants With Relapsed or Refractory Myeloma

Phase 1

Relapsed & Refractory Myeloma

A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the safety and tolerability in Japanese participants with relapsed or refractory multiple myeloma (MM) at the recommended Phase 2 dose (RP2D) identified in NCT03399799 study.

JNJ-64407564

Talquetamab

Sponsor

Janssen Pharmaceutical

---

ClinicalTrials.gov Identifier: NCT04773522

Official Title: A Phase 1 Study of JNJ-64407564, a Humanized GPRC5D * CD3 Bispecific Antibody in Japanese Subjects With Relapsed or Refractory Multiple Myeloma

First Posted : February 26, 2021

Click here to see details on ClinicalTrials.gov

A Study of JNJ-64407564 in Japanese Participants with Relapsed or Refractory Multiple Myeloma | Global Trial Finder (janssen.com)

---

JNJ-64407564 - Talquetamab

---

Location

Japan

---